The launch of Sound Bioventures Fund I resulted in broad coverage of the international life science trade media and Scandinavian financial press. Our strategy to invest in clinical, or near clinical, private companies in niche/rare indications were well presented. As Bibhash put it in Biocentury “We’ll go to the best company in the space that’s about to go clinical!”.
Broad Media Coverage of the launch of Sound Bioventures Fund I
The oral therapeutic that could change our approach to retinal disease. An inflammation-based view of both ophthalmic and neurologic health
Dr Burian said oral therapies can also function in conjunction with therapies currently on the market. In late July, biotech incubator Golgi Neurosciences S.r.l. and biopharmaceutical company Breye Therapeutics ApS announced their collaboration to develop the P2X7 receptor antagonist programme. Breye Therapeutics, a clinical-stage pharmaceutical co ...
From Doctor To Investor: How My MBA Kickstarted An Exciting Career In Life Sciences Venture Capital
Aiming to make an impact in his career, certified medical doctor Philip Brainin combined his healthcare expertise with an MBA to launch a career in life sciences venture capital A keen interest in learning and a desire to help others have defined Philip Brainin’s career so far. Today he is an analyst with a specialist […]
Sound Bioventures appoints Fredrik Lehmann as its first Entrepreneur-in-Residence
Stockholm, Sweden and Cambridge, MA, USA – 13 October 2023 – Sound Bioventures, a venture capital fund investing in about-to-be clinical or clinical stage private companies in Europe and the USA developing specialty therapeutics, today announced that Fredrik Lehmann, Ph.D., MBA has joined the company as its first Entrepreneur-in-Residence. Fr ...
At the intersection of entrepreneurship, life science, & patient needs
Fredrik Lehmann, Entrepreneur in Residence at Sound Bioventures, explains how success in life science takes tenacity and constant focus on patient needs.